CTNM

+ Watchlist + Portfolio

Contineum Therapeutics, Inc.

Regulated industry Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $12.99
52-Week Range: $8.60 – $17.79
Market Cap: $493.59M
P/E (TTM): —
EPS (TTM): -1.73
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.06
PEG Ratio: —
Return on Equity: -28.00%
Return on Assets: -19.15%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 37.17
Debt/Equity: 0.03
Total Debt: $6.57M
Free Cash Flow: $-35.14M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $263.61M

CTNM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$50.00M	$0.00	$0.00
Research & Development	$16.89M	$27.60M	$38.42M	$51.52M
Selling, General & Admin	$5.83M	$6.32M	$12.47M	$16.54M
Operating Expenses	$22.72M	$33.92M	$50.89M	$68.06M
Operating Income	-$22.72M	$16.08M	-$50.89M	-$68.06M
EBITDA	-$23.54M	$23.57M	-$50.64M	-$67.74M
Pretax Income	-$24.25M	$23.17M	-$42.26M	-$59.98M
Income Tax	$0.00	$450.00K	$0.00	—
Net Income	-$24.25M	$22.72M	-$42.26M	-$59.98M
Diluted EPS	-1.45	0.84	-2.18	-2.17
Diluted Shares	17.76M	27.06M	19.35M	27.70M

CTNM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.57M	$15.53M	$21.94M	$75.60M
Current Assets	$48.39M	$127.71M	$206.39M	$267.92M
Total Assets	$50.64M	$130.39M	$212.85M	$276.64M
Current Liabilities	$7.55M	$5.48M	$9.97M	$9.74M
Total Debt	$5.85M	$572.00K	$6.26M	$8.25M
Total Liabilities	$143.85M	$198.32M	$14.78M	$15.65M
Retained Earnings	-$97.86M	-$75.14M	-$117.40M	-$177.38M
Shareholders' Equity	-$93.21M	-$67.94M	$198.07M	$260.99M
Working Capital	$40.84M	$122.22M	$196.41M	$258.17M

CTNM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$20.12M	$19.35M	-$32.84M	-$55.31M
Capital Expenditure	-$118.00K	-$414.00K	-$514.00K	-$231.00K
Free Cash Flow	-$20.24M	$18.93M	-$33.36M	-$55.54M
Depreciation & Amortisation	$329.00K	$195.00K	$258.00K	$323.00K
Stock-Based Compensation	$1.93M	$2.22M	$6.80M	$10.04M
Investing Cash Flow	$22.30M	-$65.57M	-$69.74M	-$3.71M
Financing Cash Flow	-$1.24M	$56.18M	$109.00M	$112.69M
Share Repurchases	-$4.00K	-$28.00K	$0.00	—
Net Change in Cash	$939.00K	$9.96M	$6.42M	$53.66M

CTNM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$13.71M	$14.06M	$10.99M	$12.76M	$11.65M	$12.70M
Selling, General & Admin	$4.40M	$3.84M	$3.94M	$4.36M	$5.26M	$4.73M
Operating Expenses	$18.11M	$17.90M	$14.93M	$17.11M	$16.90M	$17.43M
Operating Income	-$18.11M	-$17.90M	-$14.93M	-$17.11M	-$16.90M	-$17.43M
EBITDA	-$18.03M	-$17.82M	-$14.85M	-$17.03M	-$16.82M	-$17.29M
Pretax Income	-$15.99M	-$16.04M	-$12.79M	-$15.16M	-$14.46M	-$15.15M
Net Income	-$15.99M	-$16.04M	-$12.79M	-$15.16M	-$14.46M	-$15.15M
Diluted EPS	-0.62	-0.62	-0.45	-0.49	-0.39	-0.40
Diluted Shares	25.87M	25.90M	28.12M	30.86M	37.34M	37.47M

CTNM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$22.47M	$20.78M	$42.63M	$75.60M	$20.16M	$14.71M
Current Assets	$192.13M	$176.84M	$184.93M	$267.92M	$252.96M	$242.58M
Total Assets	$198.26M	$182.89M	$190.85M	$276.64M	$261.35M	$250.37M
Current Liabilities	$8.95M	$7.21M	$6.36M	$9.74M	$6.66M	$6.53M
Total Debt	$6.00M	$5.75M	$5.49M	$8.25M	$6.95M	$6.57M
Total Liabilities	$13.50M	$11.50M	$10.38M	$15.65M	$11.31M	$10.71M
Retained Earnings	-$133.39M	-$149.43M	-$162.22M	-$177.38M	-$191.84M	-$206.99M
Shareholders' Equity	$184.77M	$171.39M	$180.47M	$260.99M	$250.04M	$239.66M
Working Capital	$183.19M	$169.63M	$178.57M	$258.17M	$246.31M	$236.05M

CTNM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$14.41M	-$15.66M	-$12.20M	-$13.04M	-$16.27M	-$11.50M
Capital Expenditure	-$47.00K	-$44.00K	-$98.00K	-$42.00K	-$312.00K	-$6.00K
Free Cash Flow	-$14.46M	-$15.71M	-$12.29M	-$13.08M	-$16.58M	-$11.51M
Depreciation & Amortisation	$78.00K	$79.00K	$81.00K	$85.00K	$83.00K	$134.00K
Stock-Based Compensation	$2.57M	$2.42M	$2.57M	$2.48M	$3.82M	$3.84M
Investing Cash Flow	$14.91M	$13.88M	$14.94M	-$47.45M	-$39.31M	$4.85M
Financing Cash Flow	$24.00K	$91.00K	$19.11M	$93.47M	$129.00K	$1.20M
Net Change in Cash	$527.00K	-$1.69M	$21.85M	$32.97M	-$55.45M	-$5.45M

Market Snapshot

About

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for neuroscience and immunology disorders. Headquartered in Boston, Massachusetts, the company leverages its expertise in protein science and structural biology to identify and develop small molecule drugs targeting previously undruggable proteins. Contineum's pipeline includes programs addressing serious neurological conditions and immune-mediated diseases with significant unmet medical needs. The company was formed through the merger of multiple research-driven organizations and maintains a discovery-focused approach to drug development.